GNLX — GENELUX CORPORATION COMMON STOCK (Healthcare >> Biotechnology)
GNLX FAQ
What is GNLX's ROE?
GENELUX CORPORATION COMMON STOCK reports a Return on Equity (ROE) of -138.64%.
What is GNLX's dividend yield?
GENELUX CORPORATION COMMON STOCK offers a dividend yield of 0.00%.
What is GNLX's Deepscope Quality Score?
Deepscope rates GNLX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GNLX?
Deepscope's AI Timing Score for GNLX is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GNLX belong to?
GENELUX CORPORATION COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.96
Price
0.08
(2.78%)
Day Change
|
|
|---|
GNLX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 70 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.96 |
| PBV / Sector |
5.63 / 4.91
|
| Earning Per Share | -0.73 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
0.43 M
GREAT
|
| Average 1W Daily Value |
0.38 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:13:57 |
| Symbol | GNLX |
| Name | GENELUX CORPORATION COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 44.84 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 129.14 / 9,034.83 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2625 Townsgate Road, Westlake Village, CA, United States, 91361
Phone: 805 267 9889
Website: https://www.genelux.com
Sector: Healthcare >> Biotechnology
Description: Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google